EOLS

+ Watchlist + Portfolio

Evolus, Inc.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $8.60
52-Week Range: $3.86 – $8.69
Market Cap: $551.52M
P/E (TTM): —
EPS (TTM): -0.51
Dividend Yield: —

Advanced Metrics

Price/Book: —
PEG Ratio: —
Return on Equity: —
Return on Assets: -5.40%
Gross Margin: 66.73%
Operating Margin: -3.92%
Profit Margin: -10.85%
Current Ratio: 1.70
Debt/Equity: —
Total Debt: $164.80M
Free Cash Flow: $-1.16M
Revenue Growth: 21.20%
Earnings Growth: —
Enterprise Value: $671.16M

EOLS Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$148.62M	$202.09M	$266.27M	$297.18M
Cost of Revenue	$58.84M	$64.51M	$83.97M	$100.07M
Gross Profit	$89.77M	$137.57M	$182.30M	$197.11M
Research & Development	$6.74M	$15.43M	$9.17M	$9.58M
Selling, General & Admin	$141.84M	$164.94M	$198.03M	$220.79M
Operating Expenses	$149.35M	$182.55M	$209.54M	$234.71M
Operating Income	-$59.58M	-$44.98M	-$27.23M	-$37.60M
EBITDA	-$60.72M	-$41.81M	-$25.00M	-$22.53M
Pretax Income	-$74.32M	-$61.51M	-$49.76M	-$50.96M
Income Tax	$95.00K	$176.00K	$664.00K	$677.00K
Net Income	-$74.41M	-$61.69M	-$50.42M	-$51.64M
Diluted EPS	-1.33	-1.08	-0.81	-0.80
Diluted Shares	56.06M	56.92M	62.25M	64.47M

EOLS Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$53.92M	$62.84M	$86.95M	$53.83M
Receivables	$22.45M	$30.53M	$47.68M	$54.70M
Inventory	$18.85M	$11.00M	$12.16M	$26.96M
Current Assets	$100.80M	$112.42M	$151.34M	$142.92M
Total Assets	$177.98M	$189.00M	$232.57M	$225.87M
Current Liabilities	$46.51M	$48.29M	$62.96M	$75.31M
Long-Term Debt	$71.88M	$120.36M	$121.51M	$146.10M
Total Debt	$74.42M	$126.55M	$129.98M	$155.00M
Total Liabilities	$159.48M	$209.69M	$227.05M	$248.97M
Retained Earnings	-$497.29M	-$558.98M	-$609.40M	-$661.04M
Shareholders' Equity	$18.50M	-$20.69M	$5.52M	-$23.11M
Working Capital	$54.29M	$64.13M	$88.38M	$67.61M
Net Debt	$17.96M	$57.52M	$34.55M	$92.27M

EOLS Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$84.91M	-$34.01M	-$18.00M	-$42.27M
Capital Expenditure	-$2.94M	-$1.63M	-$4.82M	-$8.45M
Free Cash Flow	-$87.85M	-$35.63M	-$22.82M	-$50.72M
Depreciation & Amortisation	$4.50M	$5.87M	$6.02M	$8.74M
Stock-Based Compensation	$10.83M	$16.46M	$22.25M	$20.70M
Investing Cash Flow	-$2.94M	-$1.63M	-$4.82M	-$8.45M
Financing Cash Flow	-$4.15M	$44.64M	$47.41M	$17.34M
Net Change in Cash	-$92.00M	$9.01M	$24.59M	-$33.38M

EOLS Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$68.52M	$69.39M	$68.97M	$90.30M	$73.14M
Cost of Revenue	$21.87M	$24.07M	$23.13M	$31.01M	$24.24M
Gross Profit	$46.66M	$45.32M	$45.84M	$59.29M	$48.90M
Research & Development	$2.21M	$1.84M	$2.05M	$3.48M	$2.24M
Selling, General & Admin	$56.64M	$56.67M	$52.82M	$54.66M	$51.98M
Operating Expenses	$59.68M	$59.44M	$56.01M	$59.58M	$55.76M
Operating Income	-$13.02M	-$14.12M	-$10.16M	-$291.00K	-$6.86M
EBITDA	-$12.58M	-$7.83M	-$9.20M	$7.08M	-$3.75M
Pretax Income	-$18.82M	-$17.09M	-$15.57M	$515.00K	-$10.42M
Income Tax	$72.00K	$53.00K	$167.00K	$385.00K	$256.00K
Net Income	-$18.89M	-$17.14M	-$15.74M	$130.00K	-$10.67M
Diluted EPS	-0.30	-0.27	-0.24	0.00	-0.16
Diluted Shares	63.70M	64.54M	64.73M	65.35M	65.19M

EOLS Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$67.89M	$61.74M	$43.52M	$53.83M	$49.79M
Receivables	$47.45M	$47.71M	$50.44M	$54.70M	$52.22M
Inventory	$10.03M	$26.46M	$32.87M	$26.96M	$24.80M
Current Assets	$131.72M	$144.97M	$134.89M	$142.92M	$138.92M
Total Assets	$213.36M	$228.80M	$219.00M	$225.87M	$220.65M
Current Liabilities	$56.23M	$63.75M	$66.71M	$75.31M	$68.02M
Long-Term Debt	$121.81M	$145.47M	$145.78M	$146.10M	$156.41M
Total Debt	$130.20M	$154.91M	$154.89M	$155.00M	$164.90M
Total Liabilities	$219.97M	$247.46M	$247.76M	$248.97M	$249.43M
Retained Earnings	-$628.29M	-$645.43M	-$661.17M	-$661.04M	-$671.71M
Shareholders' Equity	-$6.60M	-$18.65M	-$28.76M	-$23.11M	-$28.78M
Working Capital	$75.48M	$81.22M	$68.18M	$67.61M	$70.90M
Net Debt	$53.91M	$83.74M	$102.26M	$92.27M	$106.62M

EOLS Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	-$15.63M	-$24.79M	-$14.67M	$12.83M	-$9.95M
Capital Expenditure	-$1.86M	-$2.27M	-$2.16M	-$2.17M	-$1.69M
Free Cash Flow	-$17.49M	-$27.06M	-$16.83M	$10.66M	-$11.64M
Depreciation & Amortisation	$1.82M	$2.05M	$2.28M	$2.59M	$2.69M
Stock-Based Compensation	$5.93M	$4.49M	$5.13M	$5.15M	$5.12M
Investing Cash Flow	-$1.86M	-$2.27M	-$2.16M	-$2.17M	-$1.69M
Financing Cash Flow	-$1.63M	$20.66M	-$1.77M	$77.00K	$7.62M
Net Change in Cash	-$19.12M	-$6.39M	-$18.60M	$10.74M	-$4.02M

Market Snapshot

About

Evolus is a performance beauty company focused on delivering innovative aesthetic products. The company's flagship product is Jeuveau, a proprietary neurotoxin used for the temporary improvement of moderate to severe glabellar lines. Evolus markets its products primarily to medical aesthetic practitioners in the United States. The company competes in the growing medical aesthetics market with a focus on building customer loyalty and expanding its product portfolio.